Format

Send to

Choose Destination
Ann Pharmacother. 2004 Jun;38(6):1060-4. Epub 2004 Apr 30.

Coronary event secondary prevention with statins irrespective of LDL-cholesterol.

Author information

1
The Medical Center of Aurora, 1501 S. Potomac Street, Aurora, CO 80012-5411, USA. leslie.kerst@HealthONEcares.com

Abstract

OBJECTIVE:

To review the evidence for statin secondary prevention of coronary artery disease in patients with near-optimal or optimal low-density lipoprotein cholesterol (LDL-C).

DATA SOURCES:

A MEDLINE search (1966-October 2003) was conducted using the search terms HMG-CoA reductase inhibitor, statins, coronary disease, post-myocardial infarction, and average cholesterol.

DATA SYNTHESIS:

Secondary prevention trials enrolling subjects with near-optimal (<130 mg/dL) or optimal (<100 mg/dL) baseline LDL-C were included. Early statin secondary prevention studies suggested attenuated benefit, but more recent trials challenge this finding.

CONCLUSIONS:

Statin secondary prevention of coronary artery disease in patients near goal LDL-C is controversial, but recent trial results show promise.

PMID:
15121997
DOI:
10.1345/aph.1D166
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center